Hepatorenal syndrome: Pathogenesis and novel pharmacological targets

Current Opinion in Pharmacology

Volumn 4, Issue 2, 2004, Pages 189-197

  Barada, Kassem ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTISENSE OLIGONUCLEOTIDE; CAPSAICIN; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); DOPAMINE; FRESH FROZEN PLASMA; FUROSEMIDE; HORMONE RECEPTOR STIMULATING AGENT; ISOSORBIDE MONONITRATE; MIDODRINE; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; NORADRENALIN; NORFLOXACIN; OCTREOTIDE; ORNIPRESSIN; PENTOXIFYLLINE; PLACEBO; PLASMA SUBSTITUTE; PROPRANOLOL; PROSTAGLANDIN A1; PROSTAGLANDIN E2; TERLIPRESSIN; VASOCONSTRICTOR AGENT; VASODILATOR AGENT; VASOPRESSIN DERIVATIVE;

ANGINA PECTORIS; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG TARGETING; HEART ARRHYTHMIA; HEPATORENAL SYNDROME; HUMAN; HYPERTENSION; HYPOTENSION; INTESTINE ISCHEMIA; KIDNEY BLOOD VESSEL; KIDNEY FAILURE; KIDNEY ISCHEMIA; LIVER CIRRHOSIS; LIVER FAILURE; PRIORITY JOURNAL; REVIEW; SURVIVAL TIME; VASOCONSTRICTION;

ADRENERGIC ALPHA-AGONISTS; HEPATORENAL SYNDROME; HUMANS; RANDOMIZED CONTROLLED TRIALS; RENAL CIRCULATION; RETROSPECTIVE STUDIES; VASODILATOR AGENTS; VASOPRESSINS;

EID: 1842610649     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2003.10.007     Document Type: Review

References (80)

1. Gines A. Escorsell A. Gines P. Salo J. Jimenez V. Inglada L. Navasa M. Claria J. Rimola A. Arroyo V. et al. Incidence, predictive facors, and prognosis in hepatorenal syndrome in cirrhosis with ascites Gastroenterology 105 1993 229-236
2. Moore K. Wong F. Gines P. Bernardi M. Ochs A. Salerne F. Angeli P. Porayko M. Moreau R. Garcia-Tsao G. et al. The management of ascites in cirrhosis: report on the consensus conference of the international ascites club Hepatology 38 2003 258-266
3. Arroyo V. Gines P. Gerbes A. Dudley F. Gentilini P. Laffi G. Reynolds T. Ring-Larsen H. Scholmerich J. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis Hepatology 23 1996 164-176
4. Arroyo V. Colmenero J. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management J. Hepatol. 38 2003 S69-S89
5. Cardenas A, Gines P, Rodes J: Renal complications. In Diseases of the Liver, vol 1, edn 9. Edited by Schiff R, Sorrell M, Maddrey W. Philadelphia: Lippincott Williams & Wilkins; 2003:497-509.
6. Colombato L. Albillos A. Groszmann R. Temporal relationship of peripheral vasodilatation, plasma volume expansion and the hyperdynamic circulatory state in portal-hypertensive rats Hepatology 15 1992 323-328
7. Anadon M, Arroyo V: Ascites and spontaneous bacterial peritonitis. In Diseases of the Liver, vol 1, edn 9. Edited by Schiff R, Sorrell M, Maddrey W. Philadelphia: Lippincott Williams & Wilkins; 2003:559-594.
8. Schrier R. Arroyo V. Bernardi M. Epstein M. Henriksen J. Rodes J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis Gastroenterology 8 1988 1151-1157
9. Lopez C. Jimenez W. Arroyo V. Claria J. La Villa G. Asbert M. Gaya G. Rivera F. Rodes J. Temporal relationship between the decrease in arterial pressure and sodium retention in conscious spontaneously hypertensive rats with carbon tetrachloride-induced cirrhosis Hepatology 13 1991 585-589
10. Platt J. Ellis J. Rubin J. Merion R. Lucey M. Renal doppler ultrasonography: a noninvasive predictor of kidney dysfunction and hepatorenal failure in liver disease Hepatology 20 1994 362-369
11. Blendis L. Wong F. The hyperdynamic circulation in cirrhosis: an overview Pharmacol. Ther. 89 2001 221-231
12. Arroyo V. Guevara M. Gines P. Hepatorenal syndrome in cirrhosis: pathogenesis and treatment Gastroenterology 122 2002 1658-1676
13. Helmy A. Newby D. Jalan R. Johnston N. Hayes P. Webb D. Nitric oxide mediates the reduced vasoconstrictor response to angiotensin II in patients with preascitic cirrhosis J. Hepatol. 38 2003 44-50
14. Newby D. Hayes P. Hyperdynamic circulation in liver cirrhosis: not peripheral vasodilatation but 'splanchnic steal' Q. J. Med. 95 2002 827-830
15. Gines P, Cardenas A, Schrier R: Liver disease and the kidney. In Diseases of the Kidney and Urinary Tract, vol 3, edn 7. Edited by Schrier R. Philadelphia: Lippincott Williams & Wilkins; 2001:2167-2203.
16. Martin P. Gines P. Schrier R. Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis N. J. Med. 339 1998 533-541
17. Epstein M. Goligorsky M. Endothelin and nitric oxide in hepatorenal syndrome: a balance reset J. Nephrol. 10 1997 120-135
18. Wiest R. Groszmann R. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough Hepatology 35 2002 478-491
19. Dagher L. Moore K. The hepatorenal syndrome Gut 49 2001 729-737
20. Heras D. Fernandez J. Gines P. Cardenas A. Ortega R. Navasa M. Barbera J. Galahorra B. Guevara M. Bataller R. et al. Increased production of carbon monoxide in patients with cirrhosis with and without spontaneous bacterial peritonitis Hepatology 38 2003 452-459
21. Guevara M. Gines P. Jimenez V. Sort P. Fenandez-Esparrach G. Ascorsell A. Bataller R. Bosch J. Arroyo V. Rivera F. et al. Increased adrenomedullin levels in cirrhosis: relationship with hemodynamic abnormalities and vasoconstrictor systems Gastroenterology 114 1998 336-343
22. Ros J. To-figueras J. Planaguma A. Cejudo-Martin P. Fernandez-Varo J. Martin-Ruiz R. Arroyo V. Rivera F. Rodes J. Jimenez W. Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat Gastroenterology 122 2002 85-93
23. Batkai S. Jarai Z. Wagner J. Goparaju S. Varga K. Liu J. Wang L. Mirshahi F. Khanolkar A. Makriyannis A. et al. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis Nat. Med. 7 2001 827-832
24. Iwakiri Y. Cadelina G. Sessa W. Groszmann R. Mice with targeted deletion of eNOS develop hyperdynamic circulation associated with portal hypertension Am. J. Physiol. Gastrointest Liver Physiol. 283 2002 G1074-G1081
25. Henriksen J. Ring-Larsen H. Hepatorenal disorders: role of the sympathetic nervous system Semin. Liver Dis. 14 1994 35-43
26. Bernardi M. Trevisani F. Gasbarrini A. Gasbarrini G. Hepatorenal disorders: role of the renin-angiotensin-aldosterone system Semin Liver Dis. 14 1994 23-34
27. Pasqualetti P. Festuccia V. Collaciani A. Acitelli P. Casale R. Circadian rhythm of arginine vasopressin in hepatorenal syndrome Nephron 78 1998 33-37
28. Tadashi I. Atsushi T. Masahiro S. Kazuhito O. Teruhiro S. Chizuru T. Ryohichi N. Kyuichi T. Effect of posture-induced blood volume expansion on systemic and regional hemodynamics in patients with cirrhosis J. Hepatol. 27 1997 484-491
29. Bernardi M. Bassi S. Arienti V. Collibus C. Scialpi C. Buriani L. Zanzani S. Caraceni P. Trevisani F. Systemic and regional hemodynamics in pre-ascitic cirrhosis: effects of posture J. Hepatol. 39 2003 502-508
30. Magri P. Auletta M. Andreucci M. Somma G. Musone D. Fiorillo M. Torraca S. Antoniello S. Cianciaruso B. Sodium retention in preascitic stage of cirrhosis Semin Nephrol. 21 2001 317-322
31. Bernardi M. Di Marco C. Trevisani F. De Collibus C. Fornale L. Baraldini M. Andreone P. Cursaro C. Zaca F. Ligabue A. et al. The hemodynamic status of preascitic cirrhosis: an evaluation under steady-state conditions and after postural change Hepatology 16 1992 341-346
32. La Villa G. Salmeron J. Arroyo V. Bosch J. Gines P. Garcia-Pagan J. Gines A. Asbert M. Jimenez W. Rivera F. et al. Mineralocorticoid escape in patients with compensated cirrhosis and portal hypertension Gastroenterology 102 1992 2114-2119
33. Wong F. Liu P. Blendis L. The mechanism of improved sodium homeostasis of low-dose losartan in preascitic cirrhosis Hepatology 35 2002 1449-1458
34. Pozzi M. Grassi G. Redaelli E. Dell'Oro R. Ratti L. Redaelli A. Foglia G. Di Lileo A. Mancia G. Patterns of regional sympathetic nerve traffic in pre-ascitic and ascetic cirrhosis Hepatology 34 2001 1113-1118
35. Trevisani F. Colantoni F. Sica G. Gasbarrini A. D'Intino P. De Notariis S. De Jazo R. Barbieri A. Morselli A. Gasbarrini G. et al. High plasma level of atrial natriuretic peptide in preascitic cirrhosis: indirect evidence of reduced effectiveness of the peptide Hepatology 22 1995 132-137
36. Bernardi M. Renal sodium retention in preascitic cirrhosis: expanding knowledge, enduring uncertainties Hepatology 35 2002 1544-1547
37. Schrier R. Renin angiotensin in preascitic cirrhosis: evidence for primary peripheral arterial vasodilatation Gastroenterology 115 1998 489-491
38. Li Y. Song D. Zhang Y. Lee S. Effect of neonatal capsaicin treatment on haemodynamics and renal function in cirrhotic rats Gut 52 2003 293-299
39. Song D. Liu H. Sharkey K.A. Lee S. Hyperdynamic circulation in portal-hypertensive rats is dependent on central c-fos gene expression Hepatology 35 2002 159-166
40. Jonassen T. Brond L. Torp M. Graebe M. Nielsen S. Skott O. Marcussen N. Christensen S. Effects of renal denervation on tubular sodium handling in rats with CBL-induced liver cirrhosis Am. J. Physiol. Renal Physiol. 284 2003 F555-F563
41. Ming Z. Smyth D. Lautt W. Decreases in portal flow trigger a hepatorenal reflex to inhibit renal sodium and water excretion in rats: role of adenosine Hepatology 35 2002 167-175
42. La vi lla G. Barletta G. Romanelli R. Laffi G. Del Bene R. Vizzutti F. Pantaleo P. Mazzocchi V. Gentilini P. Cardiovascular effects of canrenone in patients with preascitic cirrhosis Hepatology 35 2002 1441-1448
43. Ros J. Claria J. Jimenez W. Bosch-Marce M. Angeli P. Arroyo V. Rivera F. Rodes J. Role of nitric oxide and prostacyclin in the control of renal perfusion in experimental cirrhosis Hepatology 22 1995 915-920
44. Laffi G. La Villa G. Pinzani M. Marra F. Gentilini P. Arachidonic acid derivatives and renal function in liver cirrhosis Semin Nephrol. 17 1997 530-548
45. Piscaglia F. Zironi G. Gaiani S. Ferlito M. Rappezzi C. Siringo S. Gaie C. Gramantiari L. Bolondi L. Relationship between splanchnic, peripheral and cardiac haemodynamics in liver cirrhosis of different degrees of severity Eur. J. Gastroenterol. Hepatol 9 1997 799-804
46. Henriksen J. Bendtsen F. Sorensen T. Stadeager C. Ring-Larsen H. Reduced central blood volume in cirrhosis Gastroenterology 97 1989 1506-1513
47. Colle I. Moreau R. Pessione F. Rassiat E. Heller J. Chagneau C. Pateron D. Barriere E. Condat B. Sogni P. et al. Relationships between haemodynamic alterations and the development of ascites or refractory ascites in patients with cirrhosis Eur. J. Gastroenterol. Hepatol. 13 2001 251-256
48. Epstein M. Hepatorenal syndrome: emerging perspectives Semin Nephrol. 17 1997 563-575
49. Fernandez-Seara J. Prieto J. Quiroga J. Zozaya J. Cobos M. Rodriguez-Eire J. Garcia-Plaza A. Leal J. Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure Gastroenterology 97 1989 1304-1312
50. Moore K. Wendom J. Frazer M. Karani J. Williams R. Badr K. Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome N. Engl. J. Med. 327 1992 1774-1778
51. Bakr A. Abdalla A. El-Marsafawy H. Abu-Hashem I. El-Regal M. Am T. Abdel-Khalik M. Mostafa H. A-Kader H.H. Plasma endothelin-1 concentrations in children with cirrhosis and their relationship to renal function and the severity of portal hypertension J. Pediatr. Gastroenterol. Nutr. 35 2002 149-153
52. Uriz J. Gines P. Ortega R. Jimenez W. Cardenas A. Calahorra B. Sort P. Fernandez J. Bataller R. Arroyo V. et al. Increased level of neuropeptide Y in hepatorenal syndrome J. Hepatol. 36 2002 349-355
53. Llach J. Gines P. Arroyo V. Salmeron J. Gines A. Jimenez W. Gaya J. Rivera F. Rodes J. Effect of dipyridamole on kidney function in cirrhosis Hepatology 17 1993 59-64
54. Gines P, Arroyo V, Rodes J: Renal function in cirrhosis: pathophysiology and clinical factors. In Hepatology a Textbook of Liver Disease, vol 1, edn 4. Edited by Zakim D, Boyer T. Philadelphia: Saunders; 2003:497-526.
55. Moore K. Taylor G. Maltby N. Siegers D. Fuller R. Dollery C. Williams R. Increased production of cysteinyl leukotrienes in hepatorenal syndrome J. Hepatol. 11 1990 263-271
56. Morrow J. Moore K. Awad J. Ravenscraft M. Marini G. Badr K. Williams R. Roberts L. Marked overproduction of non-cyclooxygenase derived prostanoids (F2-isoprostanes) in the hepatorenal syndrome J. Lipid Mediat. 6 1993 417-420
57. Moller S. Henriksen J. Cirrhotic cardiomyopathy: a pathophysioligical review of circulatory dysfunction in liver disease Heart 87 2002 9-15
58. Ma Z. Lee S. Cirrhotic cardiomyopathy: getting to the heart of the matter Hepatology 24 1996 451-459
59. Chan C. Hwang S. Lee F. Wang S. Chang F. Li C. Chu C. Lu R. Lee S. Prognostic value of plasma endotoxin levels in patients with cirrhosis Scand. J. Gastroenterol. 32 1997 942-946
60. Albillos A. de la Hera A. Gonzalez M. Moya J.L. Calleja J.L. Monserrat J. Ruiz-del-Arbol L. Alvarez-Mon M. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement Hepatology 37 2003 208-217
61. Hadengue A. Gadano A. Moreau R. Giostra E. Durand F. Valla D. Erlinger S. Lebrec D. Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome J. Hepatol. 29 1998 565-570
62. Guevara M. Gines P. Fernandez-Esparrach G. Sort P. Salmeron J. Jimenez W. Arroyo V. Rodes J. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion Hepatology 27 1998 35-41
63. Uriz J. Gines P. Cardenas A. Sort P. Jimenez W. Salmeron J. Bataller R. Mas A. Navasa M. Arroyo V. et al. Terlipressin plus albumin imfusion: an effective and safe therapy of hepatorenal syndrome J. Hepatol. 33 2000 43-48
64. Mulkay J.-P. Louis H. Bourgeois N. Adler M. Deviere J. Le Moine O. Long term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study Acta Gastroenterol. Belg. 64 2001 15-19
65. Colle I. Durand F. Pessione F. Rassiat E. Berneau J. Barriere E. Lebrec D. Valla D. Moreau R. Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with terlipressin: a retrospective analysis J. Gastroenterol. Hepatol. 17 2002 882-888
66. Moreau R. Durand F. Poynard T. Duhamel C. Cervon J. Ichi P. Abergel A. Halimi C. Pauwels M. Bronowicki J. et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study Gastroenterology 122 2002 923-930
67. Halimi C. Bonnard P. Bernard B. Mathurin P. Mofredj A. di Martino V. Demontis R. Henry-Biabaud H. Fievet P. Opolon P. et al. Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study Eur. J. Gastroenterol. Hepatol. 14 2002 153-158
68. Ortega R. Gines P. Uriz J. Cardenas A. Calahorra B. De Las Heras D. Guevara M. Bataller R. Jimenez W. Arroyo V. et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective nonrandomized study Hepatology 36 2002 941-948
69. Alessandria C. Venon W. Marzano A. Barletti C. Fadda M. Rizetto M. Renal failure in cirrhotic patients: role of terlipressin in clinical approsch to hepatorenal syndrome type 2 Eur. J. Gastroenterol. Hepatol. 14 2002 1363-1368
70. Solanki P. Chawla A. Garg R. Gupta R. Jain M. Sarin S. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial J. Gastroenterol. Hepatol. 18 2003 152-156
71. Angeli P. Volpin R. Gerunda G. Craighero R. Roner P. Merenda R. Amodio P. Sticca A. Caregaro L. Maffai-Faccioli A. et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide Hepatology 29 1999 1690-1697
72. Duvoux C. Zandirenas D. Hezode C. Chauvat A. Monin J. Roudot-Thoraval F. Mallat A. Dhumeaux D. Effects of noradrenalin and albumin in patients with type 1 hepatorenal syndrome: a pilot study Hepatology 36 2002 374-380
73. Pomier-Laylargues G. Paquin S. Hassoun Z. Lafortune M. Tran A. Octreotide in hepatorenal syndrome: a randomized, double blind, placebo controlled, crossover study Hepatology 38 2003 238-243
74. Fevery J. Van Cutsem E. Nevens F. Van Steenbergen W. Verberckmoes R. De Groote J. Reversal of hepatorenal syndrome in four patients by peroral misoprostol (prostaglandin E1 analogue) and albumin administration J. Hepatol. 11 1990 153-158
75. Soper C. Latif A. Bending M. Amelioration of hepatorenal syndrome with selective endothelin-A antagonist Lancet 347 1996 1842-1843
76. Abraldes J.G. Tarantino I. Turnes J. Garcia-Pagan J.C. Rodes J. Bosch J. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis Hepatology 37 2003 902-908
77. Sort P. Navasa M. Arroyo V. Aldeguer X. Planas R. Ruiz del Arbol L. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis N. Engl. J. Med. 341 1999 403-409
78. Akriviadis E. Botla R. Briggs W. Han S. Reynolds T. Shakil O. Pentoxifylline improves short term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial Gastroenterology 119 2000 1637-1648
79. Rasaratnam B. Kaye D. Jennings G. Dudley F. Chin-Dusting J. The effect of selective intestinal decontamination on the hyperdynamic circulatory state in cirrhosis. A randomized trial Ann. Intern Med. 139 2003 186-193
80. Fiorucci S. Antonelli E. Brancaleone V. Sanpaolo L. Orlandi S. Distrutti E. Acuto G. Clerici C. Baldoni M. Soldato P. et al. NCX-1000, a nitric oxide-releasing derivative of ursodeoxycholic acid, ameliorates portal hypertension and lowers norepinephrine-induced intrahepatic resistance in the isolated and perfused rat liver J. Hepatol. 39 2003 932-939